Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin
Open Access
- 1 April 2007
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 282 (17), 12650-12660
- https://doi.org/10.1074/jbc.m700820200
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody ConstructCancer Research, 2005
- Recombinant bispecific antibodies for cancer therapyActa Pharmacologica Sinica, 2005
- Induction of Human T Lymphocyte Cytotoxicity and Inhibition of Tumor Growth by Tumor-Specific Diabody-Based Molecules Secreted from Gene-Modified Bystander CellsThe Journal of Immunology, 2003
- T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody ConstructThe Journal of Immunology, 2003
- Bispecific antibodies targeting cancer cellsBiochemical Society Transactions, 2002
- PEGylated antibodies and antibody fragments for improved therapy: a reviewAdvanced Drug Delivery Reviews, 2002
- Immunotherapeutic perspective for bispecific antibodiesImmunology Today, 2000
- Treatment of Human B Cell Lymphoma Xenografts with a CD3 × CD19 Diabody and T CellsThe Journal of Immunology, 2000
- Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokineticsJournal of Molecular Biology, 1999
- Therapeutic antibody fragments with prolonged in vivo half-livesNature Biotechnology, 1999